LeonaBio Inc
Follow $LONA
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $LONA by emailVeridion Score
BETAMEDIUM CONF · 6 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is LONA moving today?
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
LONA overview
Related filings and maps
Congress activity in LONA
No receipt-qualified filings found.
LONA contract awards, year to date.
Public federal awards linked to this ticker.
LONA lobbying filings, year to date.
Registered lobbying filings matched to LeonaBio Inc.